**Medicines Update: January 2026**

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

**New marketing authorisations**

Table 1 shows the new marketing authorisations for January 2026

TABLE 1: New marketing authorisations in January 2026

| **New Marketing Authorisations** | | | |
|---|---|---|---|
| **Product name and target species** | **Active substance** | **Authorisation Holder, territory, and distribution category** | **Therapeutic group** |
| **Food Animals** | | | |
| Cubarmix Equi 400 mg/g + 80 mg/g Oral Powder for Horses | Sulfadiazine, Trimethoprim | Dopharma Research B.V.<br><br>GB & NI, POM-V | Antimicrobial |
| Lenzelta Suspension for Injection for Cattle | *Escherichia coli, Staphylococcus aureus* | Boehringer Ingelheim Vetmedica GmbH<br><br>GB, POM-V | Inactivated Bacterial Vaccine |
| Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS Emulsion for Injection for Chickens | Avian metapneumovirus, Infectious bronchitis virus, Newcastle disease virus, Infectious bursal disease virus, Avian reovirus, Egg drop syndrome virus | MSD Animal Health UK Limited<br><br>GB, POM-V | Inactivated Viral Vaccine |
| Pereprin 5 mg/ml Pour-on Solution for Cattle, Sheep and Goats | Eprinomectin | Huvepharma NV<br><br>GB & NI, POM-V | Endectocide |
| **Non-food Animals** | | | |
| Roboxera 6 mg Chewable Tablets for Cats | Robenacoxib | KRKA, d.d., Novo mesto<br><br>NI, POM-V | Anti Inflammatory NSAID |

| | | | |
|---|---|---|---|
| Thiamavance 10 mg/ml Oral Solution for Cats | Thiamazole | VIRBAC<br><br>GB & NI, POM-V | Anti Hormone Agent |

See the VMD's Product Information Database (www.gov.uk/check-animal-medicine-licensed) for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.
The timing of the product being placed on the market is an issue for the marketing authorisation holder.

**Changes to authorisations most relevant to vets**
The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used. Details can be found on the VMD's Product Information Database (PID) at www.gov.uk/check-animal-medicine-licensed.

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID. There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

**Food producing animals**

**AviPro Salmonella Duo Lyophilisate for Use in Drinking Water (Chickens, Duck, Turkeys)**
Elanco GmbH GB & NI POM-V

Section 3.6 (and other relevant sections): Updated to include the possibility of administration of an additional (forth) dose of vaccine to chickens during lay in around the 50th week of life.

**Eraquell 18.7 mg/g Oral Paste (Horses)**
**Equimax Oral Gel for Horses**
Virbac GB POM-VPS

Section 4.9: Before the first administration, the syringe must be primed. Place the ring on the first graduation mark and remove the first jet of paste by pressing the plunger. The syringe is then ready for use.

**Florgane 300 mg/ml Suspension for Injection for Cattle and Pigs**
Emdoka bvba NI POM-V

Section 3.5: The use of this veterinary medicinal product may pose a risk for terrestrial plants, cyanobacteria and groundwater organisms.

Section 5.5: The veterinary medicinal product should not enter water courses as florfenicol may be dangerous for fish and other aquatic organisms.

**Flukiver 5% w/v Oral Suspension (Sheep)**
Elanco GmbH GB & NI POM-VPS

Section 3.12: The withdrawal period for meat and offal changed to 56 days.

**Unistrain PRRS Lyophilisate and Solvent for Suspension for Injection for Pigs**
Laboratorios Hipra SA GB POM-V

Section 4.2: Reduction of minimum age of piglets for vaccination to 3 weeks.

**Companion animals**

**Bravecto TriUNO Chewable Tablets for Dogs (Range)**
MSD Animal Health UK Limited GB POM-V

Section 3.2: Addition of a new indication: Treatment of infections with *Angiostrongylus vasorum* (the causative agent of angiostrongylosis).
Associated changes with this new indication have been made to Section 3.9 (Administration routes and dosage) and additional wording in Section 4.2 (Pharmacodynamics) under Moxidectin.

**Dexdomitor 0.1 / 0.5 mg/ml Solution for Injection (Cats, Dogs)**
Orion Corporation NI POM-V

Section 3.2: Addition of a new indication: To be administered intravenously as a constant rate infusion (CRI) in dogs and cats as part of a multimodal protocol during inhalation anaesthesia.

**Felisecto Plus Spot-on Solution for Cats (Range)**
Zoetis UK Limited GB POM-V

Section 4.2: Addition of two new indications:
1). For reduction of the risk of *Dipylidium caninum* via transmission by *Ctenocephalides felis* for one month after treatment. The effect is indirect due to the product's activity against the vector.
2). Treatment of notoedric mange (*Notoedres cati).* Associated information regarding treatment of notoedric mange has been included in Section 4.4 (Special warnings for each target species) and Section 4.9 (Amount(s) to be administered and administration route).

Section 5.1: Selamectin is active against adult fleas (*Ctenocephalides* spp.) as well as mites (*Otodectes cynotis*, *Notoedres cati*), lice (*Felicola subrostratus*) and gastrointestinal nematodes (*Toxocara cati*, *Ancylostoma tubaeforme*). Activity has also been demonstrated against heartworm (*D. immitis)* larvae.
Selamectin and sarolaner reduces the risk of infection with *Dipylidium caninum* via transmission by *Ctenocephalides felis* by killing the fleas before disease transmission occurs.

**Librela Solution for Injection for Dogs (Range)**
Zoetis UK Limited GB & NI POM-V

**NI**
Section 3.6: Adverse events updated: Addition of ataxia, urinary incontinence, anorexia, lethargy at the frequency of “rare” (1 to 10 animals in 10,000 animals treated).

**GB**
Section 4.5: Caution should be used when treating patients with the following pre-existing conditions: immune-mediated haemolytic anaemia, immune-mediated polyarthritis, immune-mediated thrombocytopenia.

Caution should be used when treating patients with pre-existing seizure disorder.

**Profender Modified release Tablets for Small, Medium and Large Dogs**
Vetoquinol SA GB POM-V

Section 3.6: Adverse events updated: Digestive tract disorders (e.g. hypersalivation, vomiting, diarrhoea), neurological disorders (e.g. tremor, incoordination), convulsion, behavioural disorders (e.g. hyperactivity), anorexia, lethargy, recumbency, hyperthermia, are currently listed at the frequency of “very rare” (<1 animal in 10,000 animals treated).

**Profender Spot-on Solution for Small, Medium and Large Cats, and Multi-dose Spot-on Solution for Cats**
Vetoquinol SA GB POM-V

Section 3.6: Adverse events updated: Neurological disorders (ataxia, tremor), hypersalivation, vomiting, diarrhoea, application site alopecia, application site pruritus, application site inflammation, behavioural disorders (hyperactivity, anxiety, vocalisation), anorexia, lethargy, are currently listed at the frequency of “very rare” (<1 animal in 10,000 animals treated).

For more information, contact the VMD at postmaster@vmd.gov.uk